PAPilar Ayuda-Durán

Pilar Ayuda-Durán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pilar Ayuda-Durán has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic interrogation of drug sensitivities in melanoma reveals potent synergistic and antagonistic drug combinations with translational potential

    by Pilar Ayuda-Durán, Robert Hanes, Leiv Rønneberg, Tine Norman Alver, Geir Frode Øy, Sissel Hauge, Aram N. Andersen, Eivind Valen Egeland, Siri Juell, Sigve Nakken, et al.

    Background Targeted therapies have become mainstream anticancer treatments, although their efficacy is limited by low response rates, drug resistance, and therapy-related toxicities. Drug combinations have the potential to overcome these challenges. However, identifying effective drug combinations is a major challenge. Methods Focusing on melanoma, we systematically interrogated drug-drug interactions to identify synergistic and antagonistic drug combinations. We screened 23 melanoma and 2 melanocyte cell lines with a library of 61 drugs belonging to 11 different drug classes. Results We have identified multiple antagonistic and synergistic drug interactions. For instance, the CDK inhibitor abemaciclib strongly reduces the antiproliferative effect of nucleosides. Interestingly, this antagonistic interaction can be converted into a potent synergistic interaction by modifying the sequence of treatment; treating cells first with abemaciclib followed by nucleoside treatment results in antagonism, whereas pretreatment with nucleoside analogs followed by abemaciclib results in strong synergy. Furthermore, strong synergy is observed between combinations of Chk1 inhibitors with nucleoside analogs, especially in cell lines with defects in DNA damage response pathways, such as mutations in TP53 or CDKN2A. A combination of low doses of a Chk1 inhibitor and a nucleoside analog also synergizes in a mouse model of melanoma using female mice and significantly reduces tumor growth without noticeable toxic side effects. Conclusions Taken together, our study underscores the importance of careful design of treatment sequence algorithms and identifies actionable drug-drug interactions for treatment of melanoma with translational potential.


  • Open Access

    Time-resolved functional genomics using deep learning reveals global hierarchical control of autophagy

    by Nathalia Chica, Aram N. Andersen, Sara Orellana-Muñoz, Ignacio Garcia, Aurélie Nguéa P, Sigve Nakken, Pilar Ayuda-Durán, Linda Håkensbakken, Sebastian W. Schultz, Eline Rødningen, et al.

    Recycling of cellular components through autophagy maintains homeostasis in changing nutrient environments. Although its core mechanisms are extensively studied, understanding of its systems-wide dynamic regulation remains limited, particularly regarding how autophagy is inactivated once nutrients are restored. Here we mapped the genetic network that controls activation and inactivation of autophagy during nitrogen changes by combining time-resolved high-content imaging, deep learning and latent feature analysis. This dataset, termed AutoDRY, categorizes 5,919 mutants based on nutrient response kinetics and their contributions to autophagosome formation and clearance. Integrating these profiles with functional and genetic network data uncovered hierarchical and multilayered control of autophagy and revealed multiple new regulatory pathways. Notably, we identified the retrograde pathway as a pivotal time-varying modulator that tunes the expression of core autophagy genes and plays a central role in autophagy inactivation. Together, this study establishes a systems-level resource to guide future investigations of autophagy.


  • Open Access

    Standardized assays to monitor drug sensitivity in hematologic cancers

    by Pilar Ayuda-Durán, Johanne U. Hermansen, Mariaserena Giliberto, Yanping Yin, Robert Hanes, Sandra Gordon, Heikki Kuusanmäki, Andrea M. Brodersen, Aram N. Andersen, Kjetil Taskén, et al.

    The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell culture protocols have enhanced the precision and clinical relevance of such screens. Indeed, drug sensitivity testing has proven diagnostically valuable for patients with advanced hematologic cancers. However, different cell types behave differently in culture and therefore require optimized drug screening protocols to ensure that their ex vivo drug sensitivity accurately reflects in vivo drug responses. For example, primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells require unique microenvironmental stimuli to survive in culture, while this is less the case for acute myeloid leukemia (AML) cells. Here, we present our optimized and validated protocols for culturing and drug screening of primary cells from AML, CLL, and MM patients, and a generic protocol for cell line models. We also discuss drug library designs, reproducibility, and quality controls. We envision that these protocols may serve as community guidelines for the use and interpretation of assays to monitor drug sensitivity in hematologic cancers and thus contribute to standardization. The read-outs may provide insight into tumor biology, identify or confirm treatment resistance and sensitivity in real time, and ultimately guide clinical decision-making.


  • Robust scoring of selective drug responses for patient-tailored therapy selection

    by Yingjia Chen, Liye He, Aleksandr Ianevski, Pilar Ayuda-Durán, Swapnil Potdar, Jani Saarela, Juho J. Miettinen, Sari Kytölä, Susanna Miettinen, Mikko Manninen, et al.

    Most patients with advanced malignancies are treated with severely toxic, first-line chemotherapies. Personalized treatment strategies have led to improved patient outcomes and could replace one-size-fits-all therapies, yet they need to be tailored by testing of a range of targeted drugs in primary patient cells. Most functional precision medicine studies use simple drug-response metrics, which cannot quantify the selective effects of drugs (i.e., the differential responses of cancer cells and normal cells). We developed a computational method for selective drug-sensitivity scoring (DSS), which enables normalization of the individual patient’s responses against normal cell responses. The selective response scoring uses the inhibition of noncancerous cells as a proxy for potential drug toxicity, which can in turn be used to identify effective and safer treatment options. Here, we explain how to apply the selective DSS calculation for guiding precision medicine in patients with leukemia treated across three cancer centers in Europe and the USA; the generic methods are also widely applicable to other malignancies that are amenable to drug testing. The open-source and extendable R-codes provide a robust means to tailor personalized treatment strategies on the basis of increasingly available ex vivo drug-testing data from patients in real-world and clinical trial settings. We also make available drug-response profiles to 527 anticancer compounds tested in 10 healthy bone marrow samples as reference data for selective scoring and de-prioritization of drugs that show broadly toxic effects. The procedure takes <60 min and requires basic skills in R.


  • Open Access

    Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia

    by Benedicte Sjo Tislevoll, Monica Hellesøy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Durán, Laure Piechaczyk, Dagim Shiferaw Tadele, et al.

  • Open Access

    Early response evaluation by single cell signaling profiling in acute myeloid leukemia

    by Benedicte Sjo Tislevoll, Monica Hellesøy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Durán, Laure Piechaczyk, Dagim Shiferaw Tadele, et al.

    Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy in a cohort of 32 acute myeloid leukemia (AML) patients, using 36-dimensional mass cytometry. Through supervised and unsupervised machine learning approaches, we find that reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy is a significant predictor of patient 5-year overall survival in this cohort. Validation by RNA sequencing shows induction of MAPK target gene expression in patients with high phospho-ERK1/2 24 h post-chemotherapy, while proteomics confirm an increase of the p38 prime target MAPK activated protein kinase 2 (MAPKAPK2). In this study, we demonstrate that mass cytometry can be a valuable tool for early response evaluation in AML and elucidate the potential of functional signaling analyses in precision oncology diagnostics.


  • Open Access

    Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

    by Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, Pilar Ayuda‐Durán, Robert Hanes, Toril Holien, Jorrit Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, et al.

    Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synergy between eight different mitogen‐activated protein kinase kinase (MEK) inhibitors and the B‐cell lymphoma 2 (Bcl‐2) antagonist venetoclax. Drug sensitivity was independent of immunoglobulin heavy‐chain gene variable region (IGVH) and tumor protein p53 (TP53) mutational status, and CLL cells from idelalisib‐resistant patients remained sensitive to the treatment. This suggests that combined MEK/Bcl‐2 inhibition may be an option for high‐risk CLL. To test whether sensitivity could be detected in other B‐cell malignancies, we performed drug testing on cell line models of CLL (n = 4), multiple myeloma (MM; n = 8), and mantle cell lymphoma (MCL; n = 7). Like CLL, MM cells were sensitive to the MEK inhibitor trametinib, and synergy was observed with venetoclax. In contrast, MCL cells were unresponsive to MEK inhibition. To investigate the underlying mechanisms of the disease‐specific drug sensitivities, we performed flow cytometry‐based high‐throughput profiling of 31 signaling proteins and regulators of apoptosis in the 19 cell lines. We found that high expression of the antiapoptotic proteins myeloid cell leukemia‐1 (Mcl‐1) or B‐cell lymphoma‐extra large (Bcl‐xL) predicted low sensitivity to trametinib + venetoclax. The low sensitivity could be overcome by combined treatment with an Mcl‐1 or Bcl‐xL inhibitor. Our findings suggest that MEK/Bcl‐2 inhibition has therapeutic potential in leukemia and myeloma, and demonstrate that protein expression levels can serve as predictive biomarkers for treatment sensitivities.


  • Open Access

    Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening

    by Iwona Grad, Robert Hanes, Pilar Ayuda-Durán, Marieke Lydia Kuijjer, Jorrit M. Enserink, Leonardo A. Meza-Zepeda, Ola Myklebost

    Sarcomas are a heterogeneous group of mesenchymal orphan cancers and new treatment alternatives beyond traditional chemotherapeutic regimes are much needed. So far, tumor mutation analysis has not led to significant treatment advances, and we have attempted to bypass this limitation by performing direct drug testing of a library of 353 anti-cancer compounds that are either FDA-approved, in clinical trial, or in advanced stages of preclinical development on a panel of 13 liposarcoma cell lines. We identified and validated six drugs, targeting different mechanisms and with good efficiency across the cell lines: MLN2238 –a proteasome inhibitor, GSK2126458 –a PI3K/mTOR inhibitor, JNJ-26481585 –a histone deacetylase inhibitor, triptolide–a multi-target drug, YM155 –a survivin inhibitor, and APO866 (FK866)–a nicotinamide phosphoribosyl transferase inhibitor. GR50s for those drugs were mostly in the nanomolar range, and in many cases below 10 nM. These drugs had long-lasting effect upon drug withdrawal, limited toxicity to normal cells and good efficacy also against tumor explants. Finally, we identified potential genomic biomarkers of their efficacy. Being approved or in clinical trials, these drugs are promising candidates for liposarcoma treatment.


  • Open Access

    A cell competition–based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

    by Dagim Shiferaw Tadele, Joseph Robertson, Richard Crispin, Maria C. Herrera, Markéta Chlubnová, Laure Piechaczyk, Pilar Ayuda-Durán, Sachin Kumar Singh, Tobias Gedde-Dahl, Yngvar Fløisand, et al.


  • Open Access

    Interferon Alpha and Kinase Inhibitor Nilotinib Increase Cell Adhesion and Tunneling Nanotubes in CML

    by Maria Omsland, Vibeke Andresen, Pilar Ayuda-Durán, Stein-Erik Gullaksen, Randi Hovland, Jorrit M. Enserink, Bjørn Tore Gjertsen

    Summary statement: This study describes the effects of tyrosine kinase inhibitors on tunneling nanotube formation via increased adhesion through β-integrin in chronic myeloid leukemia cells. The actin-containing cell-to-cell communicator tunneling nanotube (TNT) is involved in regulation of cell death threshold of leukemic cells, while the mechanism of TNT regulation is mostly unknown. We have investigated TNT formation and its response to treatment in chronic myeloid leukemia (CML) cells with the pathognomonic chimeric fusion kinase BCR-ABL1 after treatment with the tyrosine kinase inhibitor nilotinib and interferon-α. Bone marrow cells of chronic phase CML patients and the CML cell line Kcl-22 formed few or no TNTs. Nilotinib and interferon-α treatment induced TNT formation in Kcl-22 cells and were found to be linked to increased adherence to fibronectin coated surfaces by restoration of β1-integrin function. This suggests modulation of TNT cell-cell communication in CML as a novel mechanism in kinase inhibitor therapy of CML.